RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+33.9%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$1.54B
AUM Growth
+$1.54B
(+18%)
Cap. Flow
+$136M
Cap. Flow
% of AUM
8.81%
Top 10 Holdings %
Top 10 Hldgs %
73.5%
Holding
35
New
4
Increased
4
Reduced
1
Closed
8
Top Buys
| 1 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$75.7M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
$73.8M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$48.2M |
| 4 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$44M |
| 5 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
$24.4M |
Top Sells
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$127M |
| 2 |
Gyre Therapeutics
GYRE
|
$13.3M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$9.37M |
| 4 |
Viking Therapeutics
VKTX
|
$8.87M |
| 5 |
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
|
$6.72M |
Sector Composition
| 1 | Healthcare | 92.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Protara Therapeutics
TARA
$120M
| $3.28M | 0.21% | 1,337,462 | – | – |
|
|
GTHX
27
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $1.74M | 0.11% | 40,000 | – | – |
|
|
28
Gyre Therapeutics
GYRE
$703M
| – | – | -514,917 | Closed | -$13.3M |
|
29
Krystal Biotech
KRYS
$4.27B
| – | – | -496,071 | Closed | -$5.01M |
|
30
PDS Biotechnology
PDSB
$57.8M
| – | – | -285,491 | Closed | -$337K |
|
|
31
Viking Therapeutics
VKTX
$3.04B
| – | – | -2,029,396 | Closed | -$8.87M |
|
|
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – | -2,471,456 | Closed | -$6.72M |
|
|
AVXS
33
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – | -1,028,289 | Closed | -$127M |
|
|
CTIC
34
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| – | – | -56,951 | Closed | -$222K |
|
|
BHVN
35
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – | -363,636 | Closed | -$9.37M |
|